73 related articles for article (PubMed ID: 16424055)
41. 'Trained immunity': consequences for lymphoid malignancies.
Stevens WB; Netea MG; Kater AP; van der Velden WJ
Haematologica; 2016 Dec; 101(12):1460-1468. PubMed ID: 27903713
[TBL] [Abstract][Full Text] [Related]
42. Harnessing innate immunity to suppress lymphoma.
Stevenson FK; Johnson PW
J Clin Oncol; 2010 Oct; 28(28):4295-6. PubMed ID: 20697076
[No Abstract] [Full Text] [Related]
43. Expression of mouse beta defensin 2 in escherichia coli and its broad-spectrum antimicrobial activity.
Gong T; Li W; Wang Y; Jiang Y; Zhang Q; Feng W; Jiang Z; Li M
Braz J Microbiol; 2011 Jul; 42(3):1180-7. PubMed ID: 24031740
[TBL] [Abstract][Full Text] [Related]
44. Immunological treatment of leukaemias.
Mathé G
Br Med J; 1970 Nov; 4(5733):487-8. PubMed ID: 4394735
[No Abstract] [Full Text] [Related]
45. Innate lymphoid cells recruit T cells to turn up the heat on tumors.
Mills KHG
Cancer Cell; 2022 Apr; 40(4):362-364. PubMed ID: 35334205
[TBL] [Abstract][Full Text] [Related]
46. Cancer immunotherapy in mice and humans: personal observations.
Kawiak J
Folia Histochem Cytobiol; 2018; 56(1):1-10. PubMed ID: 29504116
[TBL] [Abstract][Full Text] [Related]
47. Anticancer Mechanisms and Potential Anticancer Applications of Antimicrobial Peptides and Their Nano Agents.
Dong Z; Zhang X; Zhang Q; Tangthianchaichana J; Guo M; Du S; Lu Y
Int J Nanomedicine; 2024; 19():1017-1039. PubMed ID: 38317847
[TBL] [Abstract][Full Text] [Related]
48. Designing and development of multi-epitope chimeric vaccine against Helicobacter pylori by exploring its entire immunogenic epitopes: an immunoinformatic approach.
Keshri AK; Kaur R; Rawat SS; Arora N; Pandey RK; Kumbhar BV; Mishra A; Tripathi S; Prasad A
BMC Bioinformatics; 2023 Sep; 24(1):358. PubMed ID: 37740175
[TBL] [Abstract][Full Text] [Related]
49. Membrane-disruptive peptides/peptidomimetics-based therapeutics: Promising systems to combat bacteria and cancer in the drug-resistant era.
Lin L; Chi J; Yan Y; Luo R; Feng X; Zheng Y; Xian D; Li X; Quan G; Liu D; Wu C; Lu C; Pan X
Acta Pharm Sin B; 2021 Sep; 11(9):2609-2644. PubMed ID: 34589385
[TBL] [Abstract][Full Text] [Related]
50. Tissue-specific Gene Expression Changes Are Associated with Aging in Mice.
Srivastava A; Barth E; Ermolaeva MA; Guenther M; Frahm C; Marz M; Witte OW
Genomics Proteomics Bioinformatics; 2020 Aug; 18(4):430-442. PubMed ID: 33309863
[TBL] [Abstract][Full Text] [Related]
51. Alarmins and immunity.
Yang D; Han Z; Oppenheim JJ
Immunol Rev; 2017 Nov; 280(1):41-56. PubMed ID: 29027222
[TBL] [Abstract][Full Text] [Related]
52. Alarmins and Antitumor Immunity.
Nie Y; Yang D; Oppenheim JJ
Clin Ther; 2016 May; 38(5):1042-53. PubMed ID: 27101817
[TBL] [Abstract][Full Text] [Related]
53. Anti-tumor angiogenesis effect of genetic fusion vaccine encoding murine beta-defensin 2 and tumor endothelial marker-8 in a CT-26 murine colorectal carcinoma model.
Liu P; Xie G; Geng P; Zheng C; Li J; Pan F; Ruan Z; Liang H
Int J Clin Exp Med; 2015; 8(3):4744-52. PubMed ID: 26064415
[TBL] [Abstract][Full Text] [Related]
54. The Alarmin HMGN1 contributes to antitumor immunity and is a potent immunoadjuvant.
Wei F; Yang D; Tewary P; Li Y; Li S; Chen X; Howard OM; Bustin M; Oppenheim JJ
Cancer Res; 2014 Nov; 74(21):5989-98. PubMed ID: 25205103
[TBL] [Abstract][Full Text] [Related]
55. β-defensin 2 as an adjuvant promotes anti-melanoma immune responses and inhibits the growth of implanted murine melanoma in vivo.
Mei HF; Jin XB; Zhu JY; Zeng AH; Wu Q; Lu XM; Li XB; Shen J
PLoS One; 2012; 7(2):e31328. PubMed ID: 22348070
[TBL] [Abstract][Full Text] [Related]
56. Defensins as anti-inflammatory compounds and mucosal adjuvants.
Kohlgraf KG; Pingel LC; Dietrich DE; Brogden KA
Future Microbiol; 2010 Jan; 5(1):99-113. PubMed ID: 20020832
[TBL] [Abstract][Full Text] [Related]
57. Vaccine with beta-defensin 2-transduced leukemic cells activates innate and adaptive immunity to elicit potent antileukemia responses.
Ma XT; Xu B; An LL; Dong CY; Lin YM; Shi Y; Wu KF
Cancer Res; 2006 Jan; 66(2):1169-76. PubMed ID: 16424055
[TBL] [Abstract][Full Text] [Related]
58. Synergistic antileukemia effect of combinational gene therapy using murine beta-defensin 2 and IL-18 in L1210 murine leukemia model.
Xu B; Dong CY; Zhang F; Lin YM; Wu KF; Ma XT
Gene Ther; 2007 Aug; 14(15):1181-7. PubMed ID: 17495947
[TBL] [Abstract][Full Text] [Related]
59. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
[TBL] [Abstract][Full Text] [Related]
60. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
